Ontario Genomics Institute Invests in Stem Cell Technology at Tissue Regeneration Therapeutics
November 12, 2012 - (Ontario Genomics Institute) - "The Ontario Genomics Institute (OGI), through its Pre-Commercialization Business Development Fund (PBDF), has invested in Toronto-based Tissue Regeneration Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions, such as arthritis, diabetes and Crohn’s disease, to name a few." Read Full Article
